Last reviewed · How we verify
NCT07086469
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 trial testing Neoadjuvant immunochemotherapy in Toripalimab in 69 participants. Currently enrolling.
19 July 2029
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 20 July 2025 |
| Primary completion | 19 July 2029 |
| Estimated completion | 19 July 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neoadjuvant immunochemotherapy — full drug profile →
- Surufatinib Administration — full drug profile →
- Concurrent Chemotherapy — full drug profile →
- Radiotherapy — full drug profile →
Conditions studied
- Toripalimab — all drugs for Toripalimab →
- Surufatinib — all drugs for Surufatinib →
- Neoadjuvant Immunochemotherapy — all drugs for Neoadjuvant Immunochemotherapy →
- Chemoradiotherapy — all drugs for Chemoradiotherapy →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 80, any sex, with Toripalimab or Surufatinib. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Divergent immuno-landscapes: comparing the tumor microenvironment of Indian and Western HNSCC patients.
Kumar Rai P, Choudhary B. · · 2026 · PMID 42111272 · DOI 10.3389/fcell.2026.1725978
Verify or expand the search:
- PubMed search for NCT07086469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neoadjuvant immunochemotherapy
Trials testing the same drug.
- NCT07003620 — Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial · Phase 2 · recruiting
- NCT05974007 — Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC · recruiting
- NCT04280822 — Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma · Phase 3 · recruiting
- NCT07236320 — Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC · NA · completed
Other recruiting trials for Toripalimab
Currently open trials in the same condition.
- NCT06719700 — Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung · Phase 2 · recruiting
- NCT04278222 — Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) · Phase 2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07086469 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07086469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing